Sonlicromanol

(KH176)

Sonlicromanol is an investigational medicine. This means it is still being tested in clinical trials. It is not approved for use anywhere.

Study details

KHENERFIN (NCT06451757).

Adults
Types of mito
  • CPEO
  • MELAS
  • MIDD
  • m.3243A>G
  • fatigue
  • mitochondrial myopathy
In development Recruiting overseas
1

Manufacturer

Khondrion B.V.

2

Types of mito

Primary mitochondrial disease linked to the m.3243A>G mitochondrial DNA variant.

Which people with mito might this therapy help? 

Adults with primary mitochondrial disease linked to the m.3243A>G mitochondrial DNA variant. This can include people with:

  • MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes)
  • MIDD (maternally inherited diabetes and deafness)
  • CPEO (chronic progressive external ophthalmoplegia)
  • Mitochondrial myopathy
  • Multi-system mitochondrial disease.

Sonlicromanol is designed to reduce the effects of mitochondrial stress. Researchers are studying whether it can help with fatigue, muscle weakness and other symptoms in people with m.3243A>G primary mitochondrial disease.

What research has been done on this therapy? 

Sonlicromanol has been studied in earlier trials, including studies in adults with m.3243A>G primary mitochondrial disease and a study in children with primary mitochondrial disease.

Khondrion say it has been studied in a Phase 1 study, and the KHENERGY, KHENERGYZE, KHENEREXT and KHENERGYC studies.

A Phase 3 study, called KHENERFIN, is now testing whether sonlicromanol can reduce fatigue and improve physical ability in adults with m.3243A>G primary mitochondrial disease.

Clinical trial information

Study name

KHENERFIN (NCT06451757).

Location

Multiple sites overseas, including Europe, UK and USA. There are no Australian sites.

Who is funding the study?

Khondrion B.V.

Adults
Types of mito
  • CPEO
  • MELAS
  • MIDD
  • m.3243A>G
  • fatigue
  • mitochondrial myopathy
In development Recruiting overseas
What is this study about?

This study is testing whether sonlicromanol can reduce fatigue and the impact of fatigue on daily life.

It is also looking at whether sonlicromanol can improve physical ability, including balance and lower limb muscle strength.

Who can take part?
What therapy is being tested?
What does participation involve?
Costs and reimbursements
Risks and benefits

Important information

Taking part in a clinical trial is voluntary.

Study teams decide who can take part. 

Research takes time. Results are not immediate.

Speak with your specialist or care team before making decisions about treatment.

Find out more

Mito
Registry

Get the earliest information about emerging therapies and clinical trials.

Emerging therapies for mito

Learn about developing therapies and opportunities to take part in research.

Clinical trials explained

Trial information thumbnail

A guide to help understand participation and make informed decisions.

Mito
Foundation

We're here to support you on your mitochondrial disease journey.